California Supreme Court sides with Gilead in ‘duty’ to innovate case

AI justification

Ruling weakens accountability for pharmaceutical innovation, risking delays in life-saving treatments and public health equity. | The ruling prioritizes legal certainty and corporate autonomy over potential obligations to accelerate medical innovation, which could delay access to critical treatments. While it reduces litigation risks for pharmaceutical companies, it weakens accountability mechanisms for public health outcomes, particularly for vulnerable populations. The net ethical impact leans